Kuraś Renata, Stępnik Maciej, Grobelny Jarosław, Tomaszewska Emilia, Stanisławska Magdalena, Domeradzka-Gajda Katarzyna, Wąsowicz Wojciech, Janasik Beata
Central Laboratory, Nofer Institute of Occupational Medicine, 8 Teresy St., 91-348 Łódź, Poland.
QSAR LAB Ltd, 3 Lipy St., 80-172 Gdańsk, Poland.
Toxicol Res. 2023 Nov 14;40(1):163-177. doi: 10.1007/s43188-023-00213-0. eCollection 2024 Jan.
There is still little literature data on the toxicity and safety of the commonly used molybdenum (Mo) disulfide which is present in the working as well as living environments. Thus, an experiment was carried out involving rats, with single and repeated intratracheal exposure (in the latter case, 7 administrations at 2-week intervals with the analysis performed after 90 days) to lower (1.5 mg Mo kg b.w.) and higher (5 mg Mo kg b.w.) doses of molybdenum(IV) sulfide nanoparticles (MoS-NPs) and microparticles (MoS-MPs). The analysis of Mo concentrations in the tail and heart blood as well as in soft tissues (lung, liver, spleen, brain), after mineralization and bioimaging, was meant to facilitate an assessment of its accumulation and potential effects on the body following short- and long-term exposure. The multi-compartment model with an exponential curve of Mo concentration over time with different half-lives for the distribution and elimination phases of MoS-MPs and MoS-NPs was observed. After 24 h of exposure, a slight increase in Mo concentration in blood was observed. Next, Mo concentration indicated a decrease in blood concentration from 24 h to day 14 (the Mo concentration before the second administration), below the pre-exposure concentration. The next phase was linear, less abrupt and practically flat, but with an increasing trend towards the end of the experiment. Significantly higher Mo concentrations in MoS-NPs and MoS-MPs was found in the lungs of repeatedly exposed rats compared to those exposed to a single dose. The analysis of Mo content in the liver and the spleen tissue showed a slightly higher concentration for MoS-NPs compared to MoS-MPs. The results for the brain were below the calculated detection limit. Results were consistent with results obtained by bioimaging technique.
关于工作和生活环境中常见的二硫化钼(Mo)的毒性和安全性,目前的文献数据仍然很少。因此,进行了一项涉及大鼠的实验,对其进行单次和重复气管内暴露(在后一种情况下,每隔2周给药7次,90天后进行分析),分别给予较低剂量(1.5毫克钼/千克体重)和较高剂量(5毫克钼/千克体重)的硫化钼纳米颗粒(MoS-NPs)和微粒(MoS-MPs)。在矿化和生物成像后,对尾巴、心脏血液以及软组织(肺、肝、脾、脑)中的钼浓度进行分析,旨在评估短期和长期暴露后钼在体内的积累情况及其对身体的潜在影响。观察到了一个多室模型,其中钼浓度随时间呈指数曲线变化,MoS-MPs和MoS-NPs在分布和消除阶段具有不同的半衰期。暴露24小时后,血液中的钼浓度略有增加。接下来,钼浓度显示从24小时到第14天(第二次给药前的钼浓度)血液浓度下降,低于暴露前的浓度。下一阶段呈线性,变化较平缓且基本平稳,但在实验结束时呈上升趋势。与单次暴露的大鼠相比,重复暴露的大鼠肺部中MoS-NPs和MoS-MPs中的钼浓度显著更高。肝脏和脾脏组织中钼含量的分析表明,MoS-NPs中的钼浓度略高于MoS-MPs。大脑的结果低于计算出的检测限。结果与通过生物成像技术获得的结果一致。